JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 682.00
+4.00 (0.59%)
Jan 22, 2026, 3:30 PM JST
JCR Pharmaceuticals Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | -3,317 | -6,414 | 7,244 | 5,412 | 19,404 | 8,653 | Upgrade |
Depreciation & Amortization | 3,166 | 3,374 | 3,197 | 1,997 | 1,945 | 1,892 | Upgrade |
Loss (Gain) From Sale of Investments | -251 | - | - | - | - | - | Upgrade |
Loss (Gain) on Equity Investments | 160 | 467 | 1,090 | - | - | - | Upgrade |
Other Operating Activities | -31 | -2,276 | 1,982 | -8,280 | -2,520 | -801 | Upgrade |
Change in Accounts Receivable | -1,290 | 2,698 | -3,797 | 4,448 | -7,402 | -205 | Upgrade |
Change in Inventory | -647 | -822 | -2,437 | -3,877 | -1,082 | -4,699 | Upgrade |
Change in Accounts Payable | 731 | -2,003 | 1,854 | -2,892 | 1,305 | 2,630 | Upgrade |
Change in Other Net Operating Assets | -575 | -510 | 179 | -2,308 | -2,361 | 2,871 | Upgrade |
Operating Cash Flow | -2,054 | -5,486 | 9,312 | -5,500 | 9,289 | 10,341 | Upgrade |
Operating Cash Flow Growth | - | - | - | - | -10.17% | 109.88% | Upgrade |
Capital Expenditures | -7,807 | -9,888 | -1,526 | -7,654 | -11,333 | -4,780 | Upgrade |
Cash Acquisitions | - | - | -600 | -6,717 | - | - | Upgrade |
Divestitures | 145 | 145 | - | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | - | - | -569 | -906 | - | -2,747 | Upgrade |
Investment in Securities | 293 | - | - | 259 | - | 193 | Upgrade |
Other Investing Activities | -249 | -131 | 5 | 16 | 8,083 | 4,044 | Upgrade |
Investing Cash Flow | -7,618 | -9,874 | -2,690 | -15,002 | -3,250 | -3,290 | Upgrade |
Short-Term Debt Issued | - | 14,805 | - | 3,000 | - | 8,320 | Upgrade |
Long-Term Debt Issued | - | 750 | 9,600 | 4,750 | 750 | 1,750 | Upgrade |
Total Debt Issued | 14,343 | 15,555 | 9,600 | 7,750 | 750 | 10,070 | Upgrade |
Short-Term Debt Repaid | - | - | -6,900 | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -750 | -2,200 | -3,050 | -750 | -650 | Upgrade |
Total Debt Repaid | -2,650 | -750 | -9,100 | -3,050 | -750 | -650 | Upgrade |
Net Debt Issued (Repaid) | 11,693 | 14,805 | 500 | 4,700 | - | 9,420 | Upgrade |
Issuance of Common Stock | 21 | 21 | - | - | - | - | Upgrade |
Repurchase of Common Stock | -2,528 | -2,530 | 15 | 10 | 10 | 13 | Upgrade |
Common Dividends Paid | -2,477 | -2,505 | -2,500 | -2,739 | -2,169 | -1,083 | Upgrade |
Other Financing Activities | -55 | -55 | -46 | -23 | -20 | -46 | Upgrade |
Financing Cash Flow | 6,654 | 9,736 | -2,031 | 1,948 | -2,179 | 8,304 | Upgrade |
Foreign Exchange Rate Adjustments | 366 | 64 | 886 | 1,099 | 612 | -22 | Upgrade |
Miscellaneous Cash Flow Adjustments | 2 | 1 | - | 1 | - | -1 | Upgrade |
Net Cash Flow | -2,650 | -5,559 | 5,477 | -17,454 | 4,472 | 15,332 | Upgrade |
Free Cash Flow | -9,861 | -15,374 | 7,786 | -13,154 | -2,044 | 5,561 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | 6148.32% | Upgrade |
Free Cash Flow Margin | -26.10% | -46.49% | 18.16% | -38.30% | -4.00% | 18.48% | Upgrade |
Free Cash Flow Per Share | -80.65 | -124.16 | 62.09 | -105.37 | -16.46 | 44.80 | Upgrade |
Cash Interest Paid | 231 | 147 | 87 | 46 | 45 | 46 | Upgrade |
Cash Income Tax Paid | 50 | 2,284 | -1,982 | 8,279 | 2,517 | 807 | Upgrade |
Levered Free Cash Flow | -8,104 | -13,174 | 4,178 | -15,235 | 4,843 | 5,053 | Upgrade |
Unlevered Free Cash Flow | -7,948 | -13,077 | 4,232 | -15,207 | 4,871 | 5,080 | Upgrade |
Change in Working Capital | -1,781 | -637 | -4,201 | -4,629 | -9,540 | 597 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.